Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

Isabel Mortimer; Lesley Anne Bissell; Elizabeth M.A. Hensor; Lukasz Kozera; Sarah L. MacKie; Agata N. Burska; Jackie L. Nam; Helen Keen; Edith Villeneuve; Helena Donica; Maya H. Buch; Philip G. Conaghan; Paul Emery; Ann W. Morgan; Jacqueline Andrews

doi:10.1093/rheumatology/kez114

Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

Isabel Mortimer, Lesley Anne Bissell, Elizabeth M.A. Hensor, Lukasz Kozera, Sarah L. MacKie, Agata N. Burska, Jackie L. Nam, Helen Keen, Edith Villeneuve, Helena Donica, Maya H. Buch, Philip G. Conaghan, Paul Emery, Ann W. Morgan, Jacqueline Andrews

Center for Life Sciences

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	1684-1686
Number of pages	3
Journal	Rheumatology (United Kingdom)
Volume	58
Issue number	9
DOIs	https://doi.org/10.1093/rheumatology/kez114
Publication status	Published - Sept 1 2019

ASJC Scopus subject areas

Rheumatology
Pharmacology (medical)

Access to Document

10.1093/rheumatology/kez114

Cite this

Mortimer, I., Bissell, L. A., Hensor, E. M. A., Kozera, L., MacKie, S. L., Burska, A. N., Nam, J. L., Keen, H., Villeneuve, E., Donica, H., Buch, M. H., Conaghan, P. G., Emery, P., Morgan, A. W., & Andrews, J. (2019). Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. Rheumatology (United Kingdom), 58(9), 1684-1686. https://doi.org/10.1093/rheumatology/kez114

Mortimer, I, Bissell, LA, Hensor, EMA, Kozera, L, MacKie, SL, Burska, AN, Nam, JL, Keen, H, Villeneuve, E, Donica, H, Buch, MH, Conaghan, PG, Emery, P, Morgan, AW & Andrews, J 2019, 'Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis', Rheumatology (United Kingdom), vol. 58, no. 9, pp. 1684-1686. https://doi.org/10.1093/rheumatology/kez114

@article{9cf14c2928c648d79eb02f5c34fd932d,

title = "Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis",

author = "Isabel Mortimer and Bissell, {Lesley Anne} and Hensor, {Elizabeth M.A.} and Lukasz Kozera and MacKie, {Sarah L.} and Burska, {Agata N.} and Nam, {Jackie L.} and Helen Keen and Edith Villeneuve and Helena Donica and Buch, {Maya H.} and Conaghan, {Philip G.} and Paul Emery and Morgan, {Ann W.} and Jacqueline Andrews",

note = "Funding Information: Funding: This study was funded internally and supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, NIHR Leeds Clinical Research Facility and Diagnostic Evaluation Co-operative and a research grant from the investigator-initiated studies program of Merck Sharp & Dohme. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, the Department of Health or Merck Sharp & Dohme. Funding Information: Disclosure statement: P.G.C. has participated in speakers bureaus or consulted for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer and Roche. M.H.B. has received research grant support and/or honoraria/consultancy fees from Pfizer, Roche-Chugai and UCB; has received honoraria/consultancy fees from AbbVie, Aurora, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Sandoz and Sanofi. P.E. has undertaken clinical trials and provided expert advice to Pfizer, Merck Sharp & Dohme, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz and Ely Lilly. E.V. has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen and UCB and research support from AbbVie. H.K. has received honoraria from Janssen and research support from Centocor and Schering-Plough. A.W.M. has received research grant support and/or honoraria/consultancy fees from Merck Sharp & Dohme, Roche-Chugai, GlaxoSmithKline and Sanofi. L.A.B. has received honoraria from UCB. The other authors have declared no conflicts of interest.",

year = "2019",

month = sep,

day = "1",

doi = "10.1093/rheumatology/kez114",

language = "English",

volume = "58",

pages = "1684--1686",

journal = "Rheumatology (United Kingdom)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

AU - Mortimer, Isabel

AU - Bissell, Lesley Anne

AU - Hensor, Elizabeth M.A.

AU - Kozera, Lukasz

AU - MacKie, Sarah L.

AU - Burska, Agata N.

AU - Nam, Jackie L.

AU - Keen, Helen

AU - Villeneuve, Edith

AU - Donica, Helena

AU - Buch, Maya H.

AU - Conaghan, Philip G.

AU - Emery, Paul

AU - Morgan, Ann W.

AU - Andrews, Jacqueline

N1 - Funding Information: Funding: This study was funded internally and supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, NIHR Leeds Clinical Research Facility and Diagnostic Evaluation Co-operative and a research grant from the investigator-initiated studies program of Merck Sharp & Dohme. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, the Department of Health or Merck Sharp & Dohme. Funding Information: Disclosure statement: P.G.C. has participated in speakers bureaus or consulted for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer and Roche. M.H.B. has received research grant support and/or honoraria/consultancy fees from Pfizer, Roche-Chugai and UCB; has received honoraria/consultancy fees from AbbVie, Aurora, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Sandoz and Sanofi. P.E. has undertaken clinical trials and provided expert advice to Pfizer, Merck Sharp & Dohme, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz and Ely Lilly. E.V. has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen and UCB and research support from AbbVie. H.K. has received honoraria from Janssen and research support from Centocor and Schering-Plough. A.W.M. has received research grant support and/or honoraria/consultancy fees from Merck Sharp & Dohme, Roche-Chugai, GlaxoSmithKline and Sanofi. L.A.B. has received honoraria from UCB. The other authors have declared no conflicts of interest.

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85072059001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072059001&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kez114

DO - 10.1093/rheumatology/kez114

M3 - Letter

C2 - 31329965

AN - SCOPUS:85072059001

SN - 1462-0324

VL - 58

SP - 1684

EP - 1686

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

IS - 9

ER -

Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this